SLA/LP Inhibitors
SLA/LP inhibitors, which stand for serine, lactamase, and penicillinase inhibitors, constitute a class of chemical compounds designed to thwart the activity of a specific group of enzymes. These enzymes, broadly classified as serine proteases, are characterized by their utilization of a serine residue at their active site to cleave peptide bonds in proteins. They are essential for numerous biological processes, including digestion, immune response, and blood coagulation. The mechanism of action for SLA/LP inhibitors involves the formation of a covalent bond with the serine residue in the active site of the enzyme. This interaction effectively "blocks" the enzyme, preventing it from interacting with its natural substrate. The inhibition of these enzymes can disrupt the cascade of reactions they typically mediate, hence SLA/LP inhibitors are critical in studying and manipulating these biological pathways.
The chemical structures of SLA/LP inhibitors are highly varied, reflecting the diversity of serine proteases they are designed to inhibit. Many of these inhibitors mimic the transition state or the intermediate of the enzymatic reaction, which allows them to bind more effectively to the enzyme than the actual substrate. This specificity and potency are achieved by designing the inhibitors to fit snugly into the substrate pocket of the enzyme, engaging in interactions with key amino acid residues that confer high affinity and selectivity. The design of SLA/LP inhibitors often involves a careful balance between hydrophobic and hydrophilic elements, allowing these compounds to navigate the complex aqueous environment of the cell and interact with the targeted enzyme. The inhibitors may also contain elements that improve their stability against metabolic breakdown, ensuring they remain active within the biological system for the required duration to effect significant inhibition.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) pathway, which can indirectly inhibit SLA/LP by reducing the phosphorylation levels of downstream proteins that may interact with SLA/LP. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor which can downregulate protein synthesis by inhibiting the mTORC1 complex. SLA/LP, being a translationally controlled protein, would have reduced functional activity due to decreased protein synthesis. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporine A is an immunosuppressant that inhibits calcineurin. By inhibiting this phosphatase, the dephosphorylation and activation of NFAT family transcription factors are reduced, potentially diminishing the expression of SLA/LP. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which blocks the AKT signaling pathway. Since the AKT pathway is involved in various cell survival and protein synthesis pathways, inhibiting it could indirectly decrease the functional activity of SLA/LP. | ||||||
WZ 4002 | 1213269-23-8 | sc-364655 sc-364655A | 10 mg 50 mg | $180.00 $744.00 | 1 | |
WZ4002 is an EGFR inhibitor that targets mutant forms of EGFR with higher selectivity than wild type. Inhibition of EGFR can decrease downstream signaling that might be necessary for the optimal activity of SLA/LP. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is an inhibitor of the TGF-beta receptor. By blocking this receptor's activity, it can prevent the activation of downstream SMAD proteins which might regulate the expression or activity of SLA/LP. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is involved in the regulation of apoptosis and cell proliferation. Inhibiting JNK could indirectly lower the functional activity of SLA/LP if it is dependent on JNK-mediated signaling. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $47.00 | 2 | |
ZM336372 is a CRAF inhibitor which could potentially disrupt the RAF/MEK/ERK signaling pathway, indirectly leading to decreased activity of SLA/LP if it is involved in this signaling pathway. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR inhibitor that can block the kinase activity of EGFR, leading to reduced signaling through pathways that may impinge upon the functional activity of SLA/LP. | ||||||